Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Crescendo Bioscience
Biotech
BioNTech builds to a Crescendo with $750M cancer research pact
BioNTech sets sights on a Crescendo deal worth $750 million in biobucks to make mRNA-based antibodies and engineered cell therapies against cancer.
Kyle LaHucik
Jan 10, 2022 9:29am
Chutes & Ladders—Ex-Gilead CMO Andrew Cheng to lead Akero
Sep 14, 2018 9:30am
Crescendo names ex-Roche leader Pisa as CMO
Sep 11, 2018 9:16am
Crescendo raises $70M to trial bispecific T-cell engager
Apr 30, 2018 8:48am
Brexit: Why U.K. life science remains optimistic
Mar 29, 2017 6:00am
In the midst of an R&D shift, Takeda inks $790M cancer collab with Crescendo
Oct 10, 2016 9:01am
